clinical trial · NCT06401044
A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease
Thyroid Eye DiseaseAMG 732Placebo
brief summary
The primary objective of Part A of this study is to investigate the safety and tolerability of AMG 732 after single subcutaneous (SC) doses. The primary objective of Part B of this study is to investigate the efficacy of AMG 732 in participants with Thyroid Eye Disease (TED) after multiple SC doses.
started
May 30, 2024
primary completion
Jan 6, 2027
completion
Dec 24, 2027
last updated
Aug 10, 2026
detailed description
Recruitment has ended for the Phase 1 portion of the study and will reopen when Phase 2 begins recruitment.
official title
A Phase 1/2, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study to Assess the Safety, Pharmacokinetics, and Efficacy of AMG 732 in Healthy Subjects and Subjects With Moderate-to-Severe Active Thyroid Eye Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol